1 – 10 of 616
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice
2025) In Nature Aging(
- Contribution to journal › Article
-
Mark
Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia
2025) In Australian and New Zealand Journal of Psychiatry(
- Contribution to journal › Article
-
Mark
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
(
- Contribution to journal › Scientific review
-
Mark
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study
(
- Contribution to journal › Article
-
Mark
Toward a biological definition of neuronal and glial synucleinopathies
(
- Contribution to journal › Article
-
Mark
The impact of disease activity and interferon-α on the nervous system in systemic lupus erythematosus
(
- Contribution to journal › Article
-
Mark
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
(
- Contribution to journal › Article
-
Mark
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease
2025) In Nature Medicine(
- Contribution to journal › Article
-
Mark
Updated appropriate use criteria for amyloid and tau PET : A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
(
- Contribution to journal › Scientific review
-
Mark
Plasma p-tau217 in Alzheimer's disease : Lumipulse and ALZpath SIMOA head-to-head comparison
(
- Contribution to journal › Article